Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion.

Festa A, Hanley AJ, Tracy RP, D'Agostino R Jr, Haffner SM.

Circulation. 2003 Oct 14;108(15):1822-30. Epub 2003 Sep 29.

3.

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events.

Ridker PM, Rifai N, Rose L, Buring JE, Cook NR.

N Engl J Med. 2002 Nov 14;347(20):1557-65.

4.

A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis.

Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, Dhillon B, Weisel RD, Li RK, Mickle DA, Stewart DJ.

Circulation. 2002 Aug 20;106(8):913-9.

5.

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.

Haffner SM, Greenberg AS, Weston WM, Chen H, Williams K, Freed MI.

Circulation. 2002 Aug 6;106(6):679-84.

6.

Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.

Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE.

Diabetes Care. 2002 Jul;25(7):1129-34.

PMID:
12087009
7.

Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study.

Festa A, D'Agostino R Jr, Tracy RP, Haffner SM; Insulin Resistance Atherosclerosis Study.

Diabetes. 2002 Apr;51(4):1131-7.

8.

Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes.

Chu NV, Kong AP, Kim DD, Armstrong D, Baxi S, Deutsch R, Caulfield M, Mudaliar SR, Reitz R, Henry RR, Reaven PD.

Diabetes Care. 2002 Mar;25(3):542-9. Erratum in: Diabetes Care 2002 May;25(5):947.

PMID:
11874944
9.

Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year.

Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D.

Circulation. 2002 Feb 19;105(7):804-9.

10.

Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.

Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM; Diabetes Prevention Program Research Group.

N Engl J Med. 2002 Feb 7;346(6):393-403.

11.

Weight loss reduces C-reactive protein levels in obese postmenopausal women.

Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET.

Circulation. 2002 Feb 5;105(5):564-9.

12.

Novel clinical markers of vascular wall inflammation.

Blake GJ, Ridker PM.

Circ Res. 2001 Oct 26;89(9):763-71. Review.

13.

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM.

JAMA. 2001 Jul 18;286(3):327-34.

PMID:
11466099
14.

Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.

Pasceri V, Cheng JS, Willerson JT, Yeh ET.

Circulation. 2001 May 29;103(21):2531-4. Erratum in: Circulation 2001 Oct 16;104(16):1992. Chang J [corrected to Cheng JS].

15.

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels.

Jialal I, Stein D, Balis D, Grundy SM, Adams-Huet B, Devaraj S.

Circulation. 2001 Apr 17;103(15):1933-5.

16.

Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

Bastard JP, Jardel C, Bruckert E, Blondy P, Capeau J, Laville M, Vidal H, Hainque B.

J Clin Endocrinol Metab. 2000 Sep;85(9):3338-42.

PMID:
10999830
17.

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

Festa A, D'Agostino R Jr, Howard G, Mykkänen L, Tracy RP, Haffner SM.

Circulation. 2000 Jul 4;102(1):42-7.

18.

Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease.

Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM.

Clin Sci (Lond). 2000 May;98(5):531-5.

PMID:
10781383
19.

Elevated C-reactive protein levels in overweight and obese adults.

Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB.

JAMA. 1999 Dec 8;282(22):2131-5.

PMID:
10591334
20.

Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study.

Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A.

Diabetes Care. 1999 Jun;22(6):920-4.

Items per page

Supplemental Content

Write to the Help Desk